Cyclophosphamide may be an effective rescue therapy for refractory lupus myocarditis presenting with severe cardiomyopathy and mitral regurgitation.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for cyclophosphamide in refractory lupus myocarditis; prospective trials needed before clinical adoption.
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with a wide range of clinical and serological manifestations. Cardiac disease among patients with SLE is common and can involve the pericardium, myocardium, valves, conduction system, and coronary arteries. We are reporting a case of SLE in a young woman that is unique is unique in that initial symptoms consisted of pericarditis and hemorrhagic tamponade which remained progressive and resistant to aggressive immunosuppressive treatment and led to severe cardiomyopathy (ejection fraction of 25%) and severe (+4) mitral regurgitation. Her immunosuppressive treatment included hydroxychloroquine, high-dose steroids, intravenous immunoglobulins, azathioprine, and mycophenolate mofetil. Her disease progression was felt to be due to underlying uncontrolled SLE because the complement levels remained persistently low throughout the entire course and PET Myocardial Perfusion and Viability study showed stable persistent active inflammation. Eventually, she was treated with cyclophosphamide which led to improvement in ejection fraction to 55% with only mild mitral regurgitation.
No takes yet. Share an insight, caveat, or question.
Marijanovich et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: